The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The approval is backed by data showing deep, durable responses and manageable tolerability
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The approval is supported by data from three pivotal clinical trials
Elanco expects Befrena to launch in the US in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
